Key facts
- Rx Redefined’s last known valuation is $77.0M (Dec 2024).
- It has raised $35.6M across 4 recorded rounds; the latest was Early Stage VC ($21.5M) in Dec 2024.
- Notable investors include Hatteras Venture Partners, Crosscut Ventures, Silverton Partners, Tusk Venture Partners, Saturn Five — 10 tracked in total.
- Rx Redefined has filed 4 Form Ds with the SEC since 2021, most recently Dec 2024 ($21.5M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Rx Redefined
Funding rounds
4 roundsAbout Rx Redefined
Developer of medical supply and billing management platform designed to create transparency between patients and physicians. The company's platform provides a compliance-focused foundation for physician-owned DMEPOS suppliers through guided onboarding, electronic ordering, supply chain integration, and routine audits, enabling patients to receive improved quality and access to care and reducing costs.
- Sector
- Healthcare
- HQ
- Arroyo Grande, CA, United States
- Founded
- 2018
- Employees
- 85
- Website
- rxredefined.com/
- Ownership
- Privately Held (backing)
Rx Redefined doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rx Redefined shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rx Redefined in its N-PORT filings yet. We sweep new filings monthly.